⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 22, 2024Open Access

Figure S6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Alexandria P. Eiken Audrey L. Smith Sydney A. Skupa Elizabeth Schmitz Sandeep Rana Sarbjit Singh Siddhartha Kumar Jayapal Reddy Mallareddy Aguirre A. de Cubas Akshay Krishna Achyuth Kalluchi M. Jordan Rowley Christopher R. D’Angelo Matthew A. Lunning R. Gregory Bociek Julie M. Vose Amarnath Natarajan Dalia El‐Gamal

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S6 shows SpiD3 inhibits NF-κB activity and diminishes CD40L-induced survival signaling in CLL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eiken et al. (2024) studied this question.

synapsesocial.com/papers/68e68fb4b6db643587616af3 https://doi.org/10.1158/2767-9764.25880264.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
2Figure S5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
3Figure S8 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
4Figure S7 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
5Figure S3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024